Shenwei Pharmaceutical (02877) announced that the profit attributable to the company's owners for the six months ended June 30, 2023 is expected to increase by about 45% to 50% compared with the same period last year (same period in 2022: RMB 331 million).
It is reported that the expected increase in profit attributable to company owners during the period is mainly due to an increase in the group's overall sales revenue of about 32% and an increase in gross profit margin and net profit margin over the same period last year. During the period, the sales of all dosage forms increased, of which the sales of injection products and traditional Chinese medicine formula granule products increased by about 37% and 34% respectively.